Transarterial embolization for the management of emergent hemoptysis in patients with primary and metastatic lung tumors Journal Article
| Authors: | Geevarghese, R.; Petre, E. N.; Ziv, E.; Santos, E.; Rodriguez, L.; Zhao, K.; Sotirchos, V. S.; Solomon, S. B.; Alexander, E. S. |
| Article Title: | Transarterial embolization for the management of emergent hemoptysis in patients with primary and metastatic lung tumors |
| Abstract: | Objectives: To evaluate the role of systemic arterial embolization in patients with primary and metastatic lung tumors presenting with hemoptysis requiring emergent management. Patients and Methods: This retrospective single-center study evaluated patients undergoing transarterial embolization for emergent hemoptysis. Endpoints included technical success, clinical success and overall survival. Clinical success was divided into partial or complete, and defined as absence (complete) or subtotal (partial) reduction in frequency and/or volume of hemoptysis in the first 24-hours following embolization. Predictive factors for clinical outcomes were evaluated using univariate analysis. Adverse events were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Results: Thirty-seven patients were identified, including 21/37 (56.8%) patients with primary lung cancer. Clinical success was achieved in 31/37 (83.8%) patients. Median overall survival was 18 days (95% CI, 10-95). Median hemoptysis-free survival was 270 days (95% CI 7 to not reached). No significant predictors of hemoptysis-free survival were identified. Prior chemotherapy (HR 2.69, 95% CI, 1.08-6.67; P = .03) was associated with poorer overall survival. History of primary lung tumor (vs. metastatic tumor) was associated with improved overall survival (HR 0.45, 95% CI, 0.21-0.95; P = 0.04). No serious adverse events (CTCAE Grade ≥ 3) were found to be directly attributable to the embolization. Conclusion: Hemoptysis requiring emergent management in patients with lung malignancy carries a poor prognosis. Transarterial embolization is feasible, safe and may be an effective management option, although further research is warranted to identify which patients are likely to derive the greatest benefit. © 2024 Elsevier Inc. |
| Keywords: | osteosarcoma; adult; cancer chemotherapy; cancer survival; clinical article; controlled study; aged; major clinical study; overall survival; iodinated poppyseed oil; side effect; systemic therapy; cancer patient; disease free survival; antineoplastic agent; colorectal cancer; cancer immunotherapy; metastasis; multiple cycle treatment; cohort analysis; lung cancer; retrospective study; bladder cancer; renal cell carcinoma; lung metastasis; lung adenocarcinoma; drug combination; surgery; leiomyosarcoma; synovial sarcoma; drug therapy; malignant peripheral nerve sheath tumor; salivary gland carcinoma; therapy; antithrombocytic agent; metastatic; gelfoam; iatrogenic disease; anticoagulant agent; hemoptysis; embolization; emergency treatment; molecularly targeted therapy; abdominal cancer; complication; clinical outcome; myoepithelial carcinoma; artery dissection; bronchodilating agent; survival prediction; arterial embolization; Common Terminology Criteria for Adverse Events; very elderly; human; male; female; article; larynx squamous cell carcinoma; median survival time; patient history of chemotherapy; squamous cell lung carcinoma; bronchial artery; anal squamous cell carcinoma; artificial embolization; pulmonary carcinoid |
| Journal Title: | Clinical Lung Cancer |
| Volume: | 26 |
| Issue: | 1 |
| ISSN: | 1525-7304 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2025-01-01 |
| Start Page: | 45 |
| End Page: | 51.e5 |
| Language: | English |
| DOI: | 10.1016/j.cllc.2024.11.008 |
| PUBMED: | 39645530 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Erica S. Alexander -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work